Invex Therapeutics Ltd (ASX:IXC)

Australia flag Australia · Delayed Price · Currency is AUD
0.0930
-0.0020 (-2.11%)
Apr 16, 2026, 11:56 AM AEST
Market Cap6.99M +25.7%
Revenue (ttm)229.08K -81.1%
Net Income-835.92K
EPS-0.01
Shares Out75.15M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,619
Average Volume26,132
Open0.0950
Previous Close0.0950
Day's Range0.0930 - 0.0950
52-Week Range0.0740 - 0.1800
Beta0.37
RSI32.46
Earnings DateMay 13, 2026

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, A... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol IXC
Full Company Profile

Financial Performance

In fiscal year 2025, Invex Therapeutics's revenue was 229,084, a decrease of -81.10% compared to the previous year's 1.21 million. Losses were -476,868, -70.95% less than in 2024.

Financial Statements